Celgene is trumpeting new mid-stage data for an experimental drug to treat psoriasis. The oral CC-10004 hit its endpoint in the trial, inspiring the company to expand its research to include other inflammatory diseases. About one in four of the patients taking the experimental drug reported a level of improvement achieved by 10 percent of the placebo group. A total of 260 patients took part in the trial. That new data prompted Celgene researchers to expand its research program to include rheumatoid arthritis, psoriatic arthritis and other conditions.
"These positive results validate the potential of our oral class of anti-inflammatory compounds," Celgene CEO Sol Barer said in a statement.
- here's the report from the San Diego Union-Tribune